title: Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation.
abstract: Viremic slow progressors (VSP) are a rare subset of HIV-infected persons who exhibit slow immunologic progression despite high viremia. The mechanisms associated with this slow progression remain to be defined. Clinical characteristics of VSP are similar to those of natural hosts for simian immunodeficiency virus (SIV), such as sooty mangabeys (SM) and African green monkeys (AGM), who maintain near-normal CD4 counts despite high-level viremia but maintain low immune activation. Immune activation is a powerful predictor of disease progression, and we hypothesized that low immune activation might also explain the VSP phenotype. Using multiparameter flow cytometry, we assessed levels of T cell activation and regulatory T cells (Treg) in blood and rectal mucosa of VSP, typical progressors, virologic controllers, and seronegative controls. We also assessed Treg function and CD4 T cell proliferative capacity in VSP. Contrary to expectations, we found that VSP subjects have high levels of T cell activation in the gastrointestinal mucosa. The ratio of Treg to CD3+ T cells in the mucosa of VSP was relatively low, potentially contributing to increased immune activation. Nonetheless, CD4+CD25- T cells isolated from these individuals displayed a comparatively weak proliferative response to anti-CD3 stimulation. These data reveal that the VSP phenotype is associated with elevated markers of mucosal immune activation and low numbers of mucosal Treg, suggesting that factors other than immune activation account for this phenotype.
authors.affiliation: Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA 95616, USA.
authors.forename: Julia M
authors.initials: JM
authors.lastname: Shaw
authors.forename: Peter W
authors.initials: PW
authors.lastname: Hunt
authors.forename: J William
authors.initials: JW
authors.lastname: Critchfield
authors.forename: Delandy H
authors.initials: DH
authors.lastname: McConnell
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Garcia
authors.forename: Richard B
authors.initials: RB
authors.lastname: Pollard
authors.forename: Ma
authors.initials: M
authors.lastname: Somsouk
authors.forename: Steven G
authors.initials: SG
authors.lastname: Deeks
authors.forename: Barbara L
authors.initials: BL
authors.lastname: Shacklett
mesh_terms: D018450:Disease Progression; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007413:Intestinal Mucosa / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D018655:Lymphocyte Count; D012007:Rectum / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D019562:Viral Load / Q000276:immunology; D014766:Viremia / Q000276:immunology* / Q000821:virology